{"id":1384,"date":"2023-04-20T13:00:00","date_gmt":"2023-04-20T13:00:00","guid":{"rendered":"https:\/\/d.ptpl.dev\/acarix\/acarix-abs-annual-report-2022\/"},"modified":"2024-08-06T12:24:45","modified_gmt":"2024-08-06T12:24:45","slug":"acarix-abs-annual-report-2022","status":"publish","type":"post","link":"https:\/\/d.ptpl.dev\/acarix\/acarix-abs-annual-report-2022\/","title":{"rendered":"Acarix AB\u2019s Annual Report 2022"},"content":{"rendered":"
\n

Acarix, a leader in acoustic and AI-based cardiac diagnostics, today announces that the Annual Report for 2022 is available as a pdf on the company's website, https:\/\/www.acarix.com\/for-investors\/financial-reports-and-calendar<\/a>. The Annual Report is available in Swedish and English.<\/p>\n<\/div>\n

\n

For more information contact:<\/strong>
Helen Ljungdahl Round, CEO, phone +1 267 809 1225, +46\u00a0730 770283, email helen.round@acarix.com<\/a>\u00a0
Christian Lindholm, CFO, phone +46\u00a0705 118333, email christian.lindholm@acarix.com<\/a><\/p>\n<\/div>\n

\n

About Acarix<\/strong><\/p>\n\n\n\n
Acarix is a Swedish medical device company that innovates solutions for rapid AI-based rule out of Coronary Artery Disease (CAD). The CE approved and FDA DeNovo cleared Acarix CADScor\u00aeSystem is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive and costly diagnostic procedures. The CADScor System uses advanced acoustics and AI-technology to rule out CAD non-invasively in less than 10 minutes, with at least 96% certainty. Acarix is listed on the Nasdaq First North Premier Growth Market in Stockholm (ticker: ACARIX). Redeye AB (+46 (0)8 121 576 90, certifiedadviser@redeye.se<\/a>) is Certified Advisor of Acarix. For more information, please visit www.acarix.com<\/a>.\u00a0<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n
\n

Attachments<\/strong>
Acarix Annual Report 2022 Eng<\/a><\/p>\n<\/div>\n